Telehealth Weight-Loss Programs: what's actually included

Telehealth weight-loss programs vary in four areas: whether labs are included or optional, how often you see a clinician, which medications are offered (GLP-1 brands, compounded options, or oral agents), and how structured follow-up is. The right fit depends on your starting health, your medication, and how much coaching you want.

Telehealth weight-loss programs have exploded in the last three years, and from the outside they look nearly identical: a landing page, a GLP-1, a monthly fee. Under the hood, they are not the same product. The four variables that actually matter — labs, clinician access, medication, and follow-up — differ enough that two patients paying similar prices can end up with very different care.

Here is how to read the differences, in plain English.

What labs should a weight-loss program look at?

What's actually useful. Obesity medicine guidelines from the AACE recommend a baseline metabolic workup for patients starting pharmacotherapy, because weight itself is downstream of thyroid function, insulin resistance, lipids, and sometimes sex hormones.

The markers worth having before a serious GLP-1 protocol usually include:

• A1c and fasting glucose — to characterize insulin resistance and screen for diabetes
• Lipid panel — triglycerides and HDL often move meaningfully with weight loss
• TSH and free T4 — because untreated hypothyroidism blunts weight loss
• Comprehensive metabolic panel — liver and kidney function, which matter for medication selection
• In some patients, testosterone (men) or a reproductive hormone panel (women) — low testosterone and PCOS both change the picture

Some telehealth programs include labs in the monthly fee. Others treat labs as optional add-ons. A third group skips labs entirely and relies on a questionnaire. None of these is automatically wrong — a 32-year-old with a recent physical and normal labs from their PCP may not need to repeat them — but you should know which model you are buying into.

How often do you actually talk to a clinician?

What visits buy you. The initial consult is the easy part; almost every program includes one. The real variable is what happens at week 6, when side effects peak, and at month 4, when weight loss often plateaus.

Programs generally fall into three tiers:

1. Message-based only. You submit a form, a clinician reviews asynchronously, and messages replace visits. Lowest friction, lowest touch. 2. Scheduled video check-ins. Typically monthly or quarterly, with messaging between. 3. On-demand clinician access. You can escalate to a video visit when something changes — a side effect, a plateau, a new symptom.

For straightforward cases, asynchronous works. For patients on higher doses, patients with comorbidities, or anyone whose response is unusual, the ability to actually talk to a clinician matters more than the branding suggests.

Which medications are on the menu?

What you're actually prescribed. This is where programs diverge most sharply.

Branded GLP-1s and GIP/GLP-1s — semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are the FDA-approved finished products. SURMOUNT-1 reported mean weight reductions of roughly 15–21% at 72 weeks with tirzepatide depending on dose, and STEP 1 reported about 14.9% with semaglutide 2.4 mg at 68 weeks. These are the trial numbers; individual response varies.

Compounded GLP-1s — several telehealth programs offer compounded semaglutide or tirzepatide. Compounded drugs are not FDA-approved as finished products, and the FDA has flagged safety concerns about unapproved GLP-1 products marketed for weight loss. The appeal is cost and availability; the trade-off is a different regulatory status.

Oral agents — metformin, bupropion/naltrexone, and in some cases phentermine. Less dramatic weight loss on average, but relevant for patients who cannot or do not want to inject.

Nothing — some programs are coaching-only. These can be appropriate for patients who do not meet clinical criteria for pharmacotherapy or who prefer a non-medication route.

Ask any program which specific products they offer and which they do not. "GLP-1" is not a single thing.

The real questionPick the program by what happens in month 4, not month 1 — plateaus, side effects, and dose decisions are where the difference between a message queue and a clinician who knows your history becomes obvious.

What does follow-up actually look like?

Where most programs quietly thin out. Weight loss is not a one-time prescription. SURMOUNT-4 showed that patients who discontinued tirzepatide after an initial lead-in regained a substantial portion of lost weight, while those who continued maintained or extended their loss. In other words, the maintenance phase is the phase.

Strong follow-up usually includes:

• A clear titration schedule and a path to pause or step down if side effects become limiting
• Repeat labs at 3–6 months when clinically relevant — especially if the baseline flagged anything
• A plan for the plateau that almost everyone hits around month 4–6
• A maintenance protocol, not just an escalation protocol

Programs that focus heavily on the first 90 days and go quiet after are selling you the easy part of the curve.

How to compare two programs side by side

When you are evaluating options, the questions that actually separate them are:

• Are labs included, optional, or absent? If optional, which markers do they run?
• Do I get scheduled clinician time, or only messaging?
• Which specific medications are offered — branded, compounded, or oral?
• What is the plan at month 4 if weight loss stalls?
• What is the plan at month 12 if it works?

A program's price tells you what it costs. Those five questions tell you what you are actually buying.

Where DirectCare AI fits

We offer blood labs as a product because, for most patients considering a GLP-1 or any serious weight-loss protocol, the markers above change how a clinician reads the case. Patients can choose to run them with us, bring recent labs from their PCP, or proceed without them when clinically appropriate — the decision is made with a clinician who sees the full context.

Medication options, when prescribed, are discussed against your history and goals rather than defaulted to a single SKU. Follow-up is structured around the inflection points — titration, plateau, maintenance — because that is where the data says the work actually happens.

Real labs when you want them, plain-English plan either way.

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. Source
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. Source
3. Garvey WT, Mechanick JI, Brett EM, et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1-203. Source
4. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Source
5. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. Source

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.